CurrentPartnering, Nov 2010, Pages: 428
The DrugDeliveryPartnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the drugdeliverypartneringagreements entered
Global Industry Analysts, Inc., Jan 2011, Pages: 378
Encouraging Feedback for Avamys™ Nasal Spray 62
Kurve Technologies Introduces Blog on Nasal DrugDelivery 62
Accentia Extends Agreement with Mayo Foundation 62
CurrentPartnering, May 2010, Pages: 263
financing deals by value since 2000
- Most active royalty financing dealmakers since 2000
- The leading royalty financing partnering resources
In Royalty Financing Terms and Agreements in Pharma, Biotech
Global Industry Analysts, Inc., April 2011, Pages: 402
Clinigene International Deploys PheedIt Solution of SAS 72
Bioseed Research India Inks Strategic Partnership Agreement
with KeyGene 72
PRAJ Partners with Novozymes 73
Mylan sells stake in Concord Biotech
PharmaVentures, Oct 2006, Pages: 161
8.2 Identifying Opportunities and Partners
8.3 Development of Commercial Relationships
9 DrugDeliveryAgreements
List of Tables
Table 1 - Typical maximum doses per administration
Table 2
CurrentPartnering, July 2011, Pages: 835
The “Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics” report provides comprehensive understanding and unprecedented access to the co-promotion and co
Espicom Business Intelligence Ltd, July 2009
platforms in development in the pharma industry
Targeting ligands
- Antibody fragment conjugate delivery
- Antibody-directed enzyme pro-drug targeted delivery
- Peptide-induced release for targeted delivery
CurrentPartnering, Nov 2010, Pages: 324
diligence to assess suitability of your proposed deal terms for partner companies
Report scope
Asset Purchase Terms and Agreements in Pharma, Biotech and Diagnostics is intended to provide the reader
Business Insights, Jan 2004, Pages: 150
&A, expounding the benefits of in-licensing and then networked growth. It also focuses on the group of small ethical, generics, drugdelivery and certain biotech firms that together constitute the specialty pharma
Datamonitor, March 2010, Pages: 114
and inherent risks of drug development
Accessing external resources and capabilities
Future outlook for licensing deals
Big Pharma evolution
Partnership agreements become more intricate as licensees look
Global Industry Analysts, Inc., Oct 2011, Pages: 897
Jersey Manufacturing
Facility 90
Celgene Acquires Abraxis BioScience 90
HUYA Partners with Quintiles to Co-Develop HBI-8000 Cancer
drug (US/China) 91
China PharmaHub Signs Agreement with Global Player
CurrentPartnering, June 2010, Pages: 411
The Discovery Stage Partnering Terms and Agreements in Pharma and Biotech report detailed understanding and analysis of how and why companies enter discovery stage licensing/business development
Global Industry Analysts, Inc., Oct 2010, Pages: 565
? 10
An Unequivocal Discussion About Ocular Drug Design and Delivery 10
Why Understanding of the Metabolic Activity of the Eye is
Important
CurrentPartnering, Oct 2010, Pages: 586
The Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the manufacturing and supply
Global Industry Analysts, Inc., April 2011, Pages: 802
into the therapeutics market in 2013. RNAi-based therapeutics, however, pose several challenges, the most prominent and still persistent being drugdelivery. In addition, safety and efficacy, stability, and stimulation
Bizacumen Inc., Nov 2009, Pages: 436
importance. The market for world prostate cancer therapeutics continues to gain traction as companies explore advancements and improvements in drugdelivery techniques translating to greater market opportunity
Global Industry Analysts, Inc., Feb 2011, Pages: 642
By Sector -
Therapeutics and DrugDelivery
Clinical Diagnostics
Drug
Discovery Tools and Biomedical Research
and Biomaterials and
Biomedical Implants (2008) (includes corresponding
Global Industry Analysts, Inc., July 2009, Pages: 558
Landmark Deals Announced or Completed by Pharma and Biotech
Companies Engaged in Developing Kinase Inhibitor Drugs,
During the Year 2008 & 2009 II-27
CurrentPartnering, Jan 2011
-present) - by industry sector
Bigpharma
Pharmaceutical
Biotech
Diagnostic
Drugdelivery
Government
Medical device
Consumer health
Specialty pharma
Generic pharma
Agricultural
Animal health
Academic
Non
